ID | 1206 |
Name of the vaccine | Spirolept |
Microbe | Bacteria |
Disease name | Leptospirosis |
Name of bacteria | Leptospira genus |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 18 to 65 years |
Description of the vaccine | Killed whole-cell Leptospiral vaccine. |
Name of the manufacturer | Imaxio |
Name of the manufacturing country | France |
Year of manufacture | 2018 |
Clinical Phase status | Clinical - Phase 4 |
Bacterial strain | Gram negative bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Four to eight doses.
Usual dose - Two injections 15 days apart, followed by a booster 4 to 6 months later. |
Mechanism of action | Anti-leptospira IgG antibody. |
Route of administration | Subcutaneous |
Indications | Prevention of leptospirosis caused by the serogroup Icterohaemorrhagiae and Copenhageni. |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Pain or swelling, fever, headache, malaise, dizziness, nausea, muscle pain, tingling in extremity, rash, hives, fatigue. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | Yes (through the urine of infected animals) |
PubMed identifier | NA |
Clinical trial number | NCT03497572 |
Reference | https://www.vidal.fr/medicaments/gammes/spirolept-13536.html |
Other name | NA |
Additional Links | NA
|